Currently, EZH2 (Enhancer of Zeste Homolog 2) inhibitors (EZH2i) are being tested in the clinic in multiple cancer indications, and this targeted cancer therapy is approved for use in epithelioid sarcoma and relapsed/refractory follicular lymphoma (1, 2). Here, EZH2 is linked to follicular lymphoma.